TIF News (IT)

THALIA 2018-2021: Europe Is Seeing A Surge In Thalassaemia, Project Results Show

THALIA 2018-2021: Europe Is Seeing A Surge In Thalassaemia, Project Results Show

“Although thalassemia has always been endemic in Europe, especially in southern European countries such as Cyprus, Greece and Italy, the disease now knows no borders and constitutes an increasing health,…
The AAC White Paper on Pyruvate Kinase Deficiency Has Just Landed on TIF’s Website

The AAC White Paper on Pyruvate Kinase Deficiency Has Just Landed on TIF’s Website

The White Paper, based on the findings of a large international survey that looked into communication between PKD patients and caregivers and haematologists, also highlights the unmet needs and perceived…
TIF Article: COVID-19 Pandemic Exacerbated Existing Problems With Thalassaemia Care

TIF Article: COVID-19 Pandemic Exacerbated Existing Problems With Thalassaemia Care

The article discusses how the COVID-19 pandemic has magnified challenges in thalassaemia care worldwide and underscores TIF’s activities throughout the coronavirus outbreak in support of patients with haemoglobinopathies. Hematology Advisor…
TIF Guide on COVID-19 Vaccinations & Therapeutic Drugs – The December Issue

TIF Guide on COVID-19 Vaccinations & Therapeutic Drugs – The December Issue

During this last fortnight, experts have scrambled to gain an understanding of the new heavily mutated variant, what kind of symptoms and illness it can cause, and whether it undermines…
TIF Signs Agreement With Resonance Health To Deploy FerriSmart®

TIF Signs Agreement With Resonance Health To Deploy FerriSmart®

FerriSmart is an AI-driven system for automated real-time measurement of liver-iron concentrate (LIC) in patients, using non-invasive MRI-based technology. Under the Letter of Agreement, TIF will engage with National Thalassaemia…
COMING UP: 1st Global Forum On Access To Safe Blood Products For Patients In Need Of Regular Transfusion – 5 November 2021

COMING UP: 1st Global Forum On Access To Safe Blood Products For Patients In Need Of Regular Transfusion – 5 November 2021

Expected Outcomes An understanding of the strategic vision and goals for blood safety and the protection of the blood supply, especially in low-income settings; A better understanding of the key…
Juggling Between The Cost And Value of New Therapies: Does Science Still Serve Patient Needs?

Juggling Between The Cost And Value of New Therapies: Does Science Still Serve Patient Needs?

In the aftermath of the withdrawal of Zynteglo, the first gene therapy for patients with β-thalassaemia, from Europe, TIF´s Executive Director, Dr Androulla Eleftheriou, reflects on the viability of the…
Back to top button